Market

Strides Pharma shares plunge over 8% on reports of warning letter from USFDA

Updated : July 17, 2019 01:18 PM IST

At 11:50 am, the share was trading at Rs 370.35 per share, down 1.98 percent on the NSE.

Intraday, the stock plunged over 8 percent to its day’s low at Rs 347.10.

Strides Pharma Science’s shares plunged 8.2 percent intraday on Wednesday after the company received a warning letter from the United States Food and Drug Administration (US FDA) citing data integrity issues.

At 11:50 am, the share was trading at Rs 370.35 per share, down 1.98 percent on the NSE. Intraday, the stock plunged over 8 percent to its day’s low at Rs 347.10.

Strides Pharma

The US FDA pointed to a quality system that does not ensure the accuracy and integrity of data. Besides the data integrity issues, the warning letter also points out issues in test results that did not meet criteria. The USFDA said the responses by Strides to the observations were inadequate.

The warning letter was issued on July 1. The company’s Puducherry facility currently manufactures 6 drugs which won’t get impacted due to the warning letter. However, the 10 drugs filed for approval from the plant will get delayed till the site is remediated, which is almost 30 percent of the company’s total drug pipeline.

Catch all the latest and live updates here on CNBC TV18 Market Live Blog.

Disclaimer: CNBCTV18.com advises users to check with certified experts before taking any investment decisions.

Strides Pharma shares plunge over 8% on reports of warning letter from USFDA

You May Also Like

RIL's retail arm receives Rs 7,500 crore from Silver Lake for 1.75% stake sale

Positive pay system for cheque payments to come into effect from Jan 1: RBI

New products in health, hygiene spike in past 6 months with 1,897 launches: Nielsen

Trending on CNBC-TV18

recommended for you